Key takeaway
Among 323 patients with frailty symptoms at a Japanese cardiology and diabetes clinic, 24% met frailty criteria and 31% had sarcopenia, while cognitive impairment affected 41% by one test and 84% by another. These are baseline figures from a single frailty clinic, so they describe a high-risk referred group, not older adults in general.
Study design
Research article
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Frailty, cognitive decline and muscle loss often travel together in older people, but how common they are in specialty clinics treating heart and metabolic disease is unknown. The authors opened a frailty clinic and described the first patients enrolled in a planned 3-year follow-up study.
Who and how
Cross-sectional baseline analysis of a prospective observational study at a frailty clinic, with 323 patients recruited mainly from a cardiology and diabetes outpatient clinic after showing symptoms suggestive of frailty. Frailty was diagnosed with the modified Cardiovascular Health Study (mCHS) criteria, cognition with the Mini-Mental State Examination (MMSE) and the Japanese Montreal Cognitive Assessment (MoCA-J), and sarcopenia with the Asian Working Group for Sarcopenia (AWGS) criteria. The abstract does not report the average age or the sex split.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Most patients had other conditions: hypertension in 78%, dyslipidemia in 63% and diabetes in 57%, with cardiovascular disease and probable heart failure also common.
- 2By the mCHS criteria 24% were frail and by AWGS criteria 31% had sarcopenia. Cognitive impairment was found in 41% using an MMSE cutoff of 27 or below, and in 84% using a MoCA-J cutoff of 25 or below.
- 3Frailty and cognitive impairment became more common with age, while sarcopenia levelled off after age 80.
- 4Having diabetes, hypertension or dyslipidemia made little difference to the rates, with a few exceptions, which the authors attribute to nearly everyone already carrying several cardiovascular conditions. Most frail and sarcopenic patients had cognitive impairment, and suspected dementia occurred in about 20% of each group.
Limits & uncertainty
- 1All patients came from one clinic and were selected for frailty symptoms, so the rates do not describe older adults with heart disease or diabetes in general.
- 2The two cognitive tests gave very different rates (41% versus 84%), so the figure depends heavily on the cutoff chosen.
- 3This is a cross-sectional snapshot, so it cannot show which condition leads to which; the planned 3-year follow-up will address that.
- 4This reading is based on the abstract only.
What to take from it
If you are older and living with heart disease or diabetes, weakness, slow walking and memory complaints are common together and worth raising with your clinician rather than treating separately. The paper does not test any treatment, and the cognitive cutoffs are screening thresholds, not diagnoses.
Reading your own data
Grip strength, walking speed, daily step count and unplanned weight loss are the kind of trends that can hint at frailty, and a wearable can log steps and gait speed over time. Compare your own numbers on the same device across weeks rather than against clinic cutoffs, and bring a downward trend to your clinician.
How to read this evidence
The index does not establish a precise design. Read the methods before making causal claims; check population, comparator, outcomes and uncertainty in the source.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Although frailty and cognitive impairment are critical risk factors for disability and mortality in the general population of older inhabitants, the prevalence and incidence of these factors in individuals treated in the specialty outpatient clinics are unknown.
Methods
We recently established a frailty clinic for comprehensive assessments of conditions such as frailty, sarcopenia, and cognition, and planned 3-year prospective observational study to identify the risk factors for progression of these aging-related statuses. To date, we recruited 323 patients who revealed symptoms suggestive of frailty mainly from a specialty outpatient clinic of cardiology and diabetes. Frailty status was diagnosed by the modified Cardiovascular Health Study (mCHS) criteria and some other scales. Cognitive function was assessed by Mini-Mental State Examination (MMSE), Japanese version of the Montreal Cognitive Assessment (MoCA-J), and some other modalities. Sarcopenia was defined by the criteria of the Asian Working Group for Sarcopenia (AWGS). In this report, we outlined our frailty clinic and analyzed the background characteristics of the subjects.
Results
Most patients reported hypertension (78%), diabetes mellitus (57%), or dyslipidemia (63%), and cardiovascular disease and probable heart failure also had a higher prevalence. The prevalence of frailty diagnosed according to the mCHS criteria, cognitive impairment defined by MMSE (≤27) and MoCA-J (≤25), and of AWGS-defined sarcopenia were 24, 41, and 84, and 31%, respectively. The prevalence of frailty and cognitive impairment increased with aging, whereas the increase in sarcopenia prevalence plateaued after the age of 80 years. No significant differences were observed in the prevalence of frailty, cognitive impairment, and sarcopenia between the groups with and without diabetes mellitus, hypertension, or dyslipidemia with a few exceptions, presumably due to the high-risk subjects who had multiple cardiovascular comorbidities. A majority of the frail and sarcopenic patients revealed cognitive impairment, whereas the frequency of suspected dementia among these patients were both approximately 20%.
Conclusions
We found a high prevalence of frailty, cognitive impairment, and sarcopenia in patients with cardiometabolic disease in our frailty clinic. Comprehensive assessment of the high-risk patients could be useful to identify the risk factors for progression of frailty and cognitive decline.
Sources & attribution
Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic.
Tamura Y, Ishikawa J, Fujiwara Y, Tanaka M, Kanazawa N, Chiba Y, Iizuka A, Kaito S, Tanaka J, Sugie M, Nishimura T, Kanemaru A, Shimoji K, Hirano H, Furuta K, Kitamura A, Seino S, Shinkai S, Harada K, Kyo S, Ito H, Araki A.
BMC geriatrics · 2018-11-06
DOI: 10.1186/s12877-018-0955-4 ↗PubMed · 30400831 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

